Glioma
Conditions
Interventions
Administration of unapproved drug, single dose, 74MBq/10mg
Sponsors
University of Tsukuba
Tsukuba Advanced Imaging Center ImaginAb, Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patient is over 20 years old at the time of informed consent (2) Karnofsky Performance Status (KPS) is 70 or more (3) Patients who have the following examination findings AST or ALT is not 2.5 fold higher than the upper normal range T-bil is not 1.5 fold higher than the upper normal range Serum albmin is more than 3.8 g/dl Serum creatinine is not 1.5 fold higher than the upper normal range Creatinine clearance is more than 60 ml/min
Exclusion criteria
Exclusion criteria: (1) Patients without operative indication (2) Patients with severe cardiovascular, respiratory, renal, gastrointestinal, hematological, or neuropsychiatric disease (3) Patients whose doctors determined as inadequate for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety: Adverse events within the 2 days after intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Imaging of tumor neovasculature 2) PET imaging condition | — |
Countries
Japan
Contacts
Public ContactMasahide Matsuda
Faculty of Medicine, University of Tsukuba Department of Neurosurgery
Outcome results
None listed